HIMA urges firms to use third-party review
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.Last month HIMA passed a
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.
Last month HIMA passed a resolution reminding companies to use the third-party review system. HIMA represents more than 800 manufacturers of medical devices, diagnostic products, and medical information systems.
The Food and Drug Administration Modernization Act, passed three years ago, devised the third-party system in response to a growing backlog of FDA applications and a dearth of personnel to complete the reviews. The act created a group of scientific and industry experts qualified to grant FDA approval for medical devices, said Linda Ruckel, HIMA spokeswoman.
HIMA members may be hesitant to use the third-party review system for product approval because they arent used to it, Ruckel said.
We believe its a good thing. A lot of times (members) will go for the old tried and true way rather than a new format, Ruckel said. We know its out there and we want to encourage (companies) to use it more.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
